Mẫu số 01-B

CÔNG TY CỔ PHẦN DƯỢC PHẨM HÀ TÂY

Số: 802 /CV-DHT

CỘNG HÒA XÃ HỘI CHỦ NGHĨA VIỆT NAM

Độc lập - Tự do - Hạnh phúc

Hà Nội, ngày 28 tháng 10 năm 2026

CÔNG BỐ THÔNG TIN ĐỊNH KỲ BÁO CÁO TÀI CHÍNH

Kính gửi: Sở Giao dịch Chứng khoán Hà Nội

Thực hiện quy định tại Khoản 3 Điều 14 Thông tư số 96/2020/TT-BTC ngày 16/11/2020 của Bộ Tài chính hướng dẫn công bố thông tin trên thị trường chứng khoán, CTCP Dược phẩm Hà Tây thực hiện công bố thông tin báo cáo tài chính (BCTC) quý 3/năm 2026 với Sở Giao dịch Chứng khoán Hà Nội như sau:

1. Tên tổ chức: CÔNG TY CỔ PHẦN DƯỢC PHẨM HÀ TÂY

- Mã chứng khoán: DHT
- Địa chỉ: Số 10A phố Quang Trung, phường Hà Đông, TP. Hà Nội
- Điện thoại liên hệ/Tel: 0433 501 117 Fax:
- Email: duochatay@gmail.com
- Website: https://www.hataphar.com.vn

2. Nội dung thông tin công bố:

- BCTC quý 3/năm 2026

[X] BCTC riêng (TCNY không có công ty con và đơn vị kế toán cấp trên có đơn vị trực thuộc);

[X] BCTC hợp nhất (TCNY có công ty con);

[ ] BCTC tổng hợp (TCNY có đơn vị kế toán trực thuộc tổ chức bộ máy kề toán riêng).

- Các trường hợp thuộc diện phải giải trình nguyên nhân:

+ Tổ chức kiểm toán đưa ra ý kiến không phải là ý kiến chấp nhận toàn phần đối với BCTC (đối với BCTC được soát xét/được kiểm toán):

[ ] Có [X] Không

Văn bản giải trình trong trường hợp tích có:

[ ] Có [ ] Không

+ Lợi nhuận sau thuế trong kỳ báo cáo có sự chênh lệch trước và sau kiểm toán từ 5% trở lên, chuyển từ lỗ sang lãi hoặc ngược lại (đối với BCTC được kiểm toán năm 2026):

[ ] Có [X] Không

Văn bản giải trình trong trường hợp tích có:

☐ Có ☐ Không

+ Lợi nhuận sau thế thu nhập doanh nghiệp tại báo cáo kết quả kinh doanh của kỳ báo cáo thay đổi từ 10% trở lên so với báo cáo cùng kỳ năm trước:

☒ Có ☐ Không

Văn bản giải trình trong trường hợp tích có:

☒ Có ☐ Không

+ Lợi nhuận sau thuế trong kỳ báo cáo bị lỗ, chuyển từ lãi ở báo cáo cùng kỳ năm trước sang lỗ ở kỳ này hoặc ngược lại:

☐ Có ☒ Không

Văn bản giải trình trong trường hợp tích có:

☐ Có ☐ Không

Thông tin này đã được công bố trên trang thông tin điện tử của công ty vào ngày: 29/10/2026 tại đường dẫn: https://www.hataphar.com.vn/thong-tin-codong.html3.

3. Báo cáo về các giao dịch có giá trị từ 35% tổng tài sản trở lên trong năm 2026: Không có

Trường hợp TCNY có giao dịch đề nghị báo cáo đầy đủ các nội dung sau:

- Nội dung giao dịch:
- Tỷ trọng giá trị giao dịch/tổng giá trị tài sản của doanh nghiệp (%) (*căn cứ trên báo cáo tài chính năm gần nhất*):
- Ngày hoàn thành giao dịch

Chúng tôi xin cam kết các thông tin công bố trên đây là đúng sự thật và hoàn toàn chịu trách nhiệm trước pháp luật về nội dung các thông tin công bố.

Đại diện tổ chức
Người đại diện theo pháp luật/Người UQCBTT
(Ký, ghi rõ họ tên, chức vụ, đóng dấu)

Tài liệu đính kèm:
- BCTC riêng Quý 3.2026
- BCTC HN Quý 3.2026
- Văn bản giải trình

CÔNG TY CỔ PHẦN DƯỢC PHẨM HÀ TÂY

TỔNG GIÁM ĐỐC
OSAMU YOMOGIDA

HATAPHAR
CÔNG TY CP DƯỢC PHẨM HÀ TÂY

No.: 803/CV-BCTC-DHT

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

Hanoi, October 28, 2026

To: The State Securities Commission of Viet Nam
Hanoi Stock Exchange

Company name: Ha Tay Pharmaceutical Joint Stock Company
Stock Code: DHT
Head office: 10A Quang Trung – Ha Dong Ward – Hanoi City
Phone: 0433 501 117 – Fax: 0433 829 054
Information disclosure officer: Mrs. Pham Minh Thu – Deputy Manager of Legal and Communications Department.

In the Consolidated financial statements for Q3 2026, the business results of Hatay Pharmaceutical Joint Stock Company are as follows:

The total profit after tax in Q3 2026 was VND 5,852,677,175, compared to VND 11,524,219,017 in Q3 2025 — a decrease of VND 5,671,541,842, equivalent to a drop of 49.21% This was mainly due to:

- Gross profit in the Q3 in 2026 amounted to VND 46,971,496,392, compared to VND 49,713,957,022 in the Q3 in 2025, a decrease of VND 2,742,460,630, equivalent to a drop of 5.52%.
- Financial income in the Q3 in 2026 amounted to VND 3,534,843,252, compared to VND 5,679,495,204 in the Q3 in 2025, a decrease of VND 2,144,651,952, equivalent to a drop of 37.76%. The decline in financial income had an adverse impact on the Company's profit for the period.
- Selling expenses and general and administrative expenses in the Q3 in 2026 totaled VND 51,233,688,983, compared to VND 43,348,793,616 in the Q3 in 2025, representing an increase of VND 7,884,895,367, equivalent to a rise of 18.2%. The increase in selling expenses and general and administrative expenses negatively affected the Company's profit for the period.

We hereby report to the State Securities Commission of Vietnam and the Hanoi Stock Exchange for your information.

Recipient:
- As above
- Archive: Office files

HA TAY PHARMACEUTICAL JOINT STOCK COMPANY
General Director

M.S.D.N: 0500391400 C.T.C.P
CÔNG TY CỔ PHẦN DƯỢC PHẨM HÀ TÂY
P. HÀ ĐÔNG - TP. HÀ NỘI

Osamu Yomogida

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

CONSOLIDATED FINANCIAL STATEMENTS

For the period from 01/07/2026 to 30/09/2026

Ha Noi, October 2026

Form B01a - DN/HN

CONSOLIDATED BALANCE SHEET

As at September 30, 2026

Unit: VND

ASSETS	Codes	Notes	30/06/2029	01/01/2026
A - CURRENT ASSETS	**100**		**695,344,962,539**	**896,739,416,323**
I. Cash and cash equivalents	**110**	**I.01**	**117,376,267,372**	**84,407,566,361**
1 Cash	111		61,676,267,372	74,036,751,569
2 Cash equivalents	112		55,700,000,000	10,370,814,792
II. Short-term financial investments	**120**		**100,286,027,330**	**153,045,424,635**
1 Held-to-maturity investments	123	I.02	100,286,027,330	153,045,424,635
III. Short-term receivables	**130**		**161,974,811,190**	**145,889,465,780**
1 Short-term trade receivables	131	I.03	129,888,272,495	111,636,095,800
2 Short- term advances to suppliers	132	I.04	35,487,273,121	37,840,076,173
3 Other short-term receivables	135	I.05	411,872,532	294,439,301
4 Provision for short-term doubtful debts	136	I.06	(3,812,606,958)	(3,881,145,494)
IV. Inventories	**140**	**I.07**	**313,838,865,367**	**513,396,959,547**
1 Inventories	141		313,838,865,367	513,396,959,547
V. Short-term biological assets	**150**		-	-
VI. Other short-term assets	**160**		**1,868,991,280**	-
1 Value added tax deductibles	162		1,868,991,280	-
B - NON-CURRENT ASSETS	**200**		**1,017,505,946,729**	**1,035,177,856,096**
I. Long-term receivables	**210**		**6,407,042,500**	**6,407,042,500**
1 Other long-term receivables	215	I.05	6,407,042,500	6,407,042,500
II. Fixed assets	**220**		**891,090,119,877**	**174,908,301,066**
1 Tangible fixed assets	221	I.08	889,713,459,877	173,531,641,066
Cost	*222*		*1,184,404,236,014*	*446,492,048,355*
Accumulated depreciation	*223*		*(294,690,776,137)*	*(272,960,407,289)*
2 Intangible fixed assets	227	I.09	1,376,660,000	1,376,660,000
Cost	*228*		*2,026,660,000*	*2,026,660,000*
Accumulated amortization	*229*		*(650,000,000)*	*(650,000,000)*
III. Long-term biological assets	**230**		-	-
IV. Investment property	**240**		-	-
V. Long-term assets in progress	**250**		**11,053,576,688**	**827,184,318,661**
1 Construction in progress	252	I.10	11,053,576,688	827,184,318,661
VI. Long-term financial investments	**260**	**I.02**	**20,651,818,815**	**19,860,292,957**
1 Investment in joint-ventures, associates	262		20,651,818,815	19,860,292,957
VII. Other long-term assets	**270**		**88,303,388,849**	**6,817,900,912**
1 Long-term prepayments expenses	271	I.11	87,589,717,980	5,632,174,250
2 Deferred tax assets	272	I.12	713,670,869	1,185,726,662
TOTAL ASSETS (280=100+200)	**280**		**1,712,850,909,268**	**1,931,917,272,419**

Form B01a - DN/HN

CONSOLIDATED BALANCE SHEET

As at September 30, 2026

(continued)

Unit: VND

	RESOURCES	Codes	Notes	30/06/2029	01/01/2026
C -	**LIABILITIES**	**300**		**576,021,541,110**	**820,716,628,095**
I.	**Current liabilities**	**310**		**489,514,993,563**	**734,022,780,548**
1	Short - term trade payables	311	I.13	237,282,018,356	261,260,793,034
2	Short - term advances from customers	312	I.14	60,393,032,031	177,983,077,668
3	Taxes and amounts payable to the State budget	314	I.15	2,611,557,218	5,515,053,039
4	Payables to employees	315		20,299,457,622	28,051,603,241
5	Short-term accrued expenses	316	I.16	1,298,653,892	161,520,303
6	Short-term unearned revenue	319	I.17	4,637,903,846	6,418,086,306
7	Other current payables	320	I.18	1,529,940,250	783,924,677
8	Short-term loans and obligations under finance leases	321	I.19	160,565,050,276	249,995,403,408
9	Bonus and welfare funds	323		897,380,072	3,853,318,872
II.	**Long-term liabilities**	**330**		**86,506,547,547**	**86,693,847,547**
1	Other long-term payables	338	I.18	3,438,300,000	3,625,600,000
2	Long-term loans and obligations under finance leases	339	I.19	83,068,247,547	83,068,247,547
D -	**EQUITY**	**400**	**I.20**	**1,136,829,368,158**	**1,111,200,644,324**
1	Owner's contributed capital	411		905,755,510,000	905,755,510,000
-	*Ordinary shares carrying voting rights*	*411a*		*905,755,510,000*	*905,755,510,000*
2	Share premium	412		37,282,220,000	37,282,220,000
3	Other owners' equity	414		2,236,413,529	26,612,306,630
4	Treasury shares	415		(8,083,874,357)	(8,083,874,357)
5	Investment and development fund	418		10,749,248,213	10,749,248,213
6	Retained earnings	420		161,928,663,654	110,355,967,042
-	*Retained earnings accumulated to the prior period*	*420a*		*134,116,766,080*	*56,699,133,435*
-	*Retained earnings of current period*	*420b*		*27,811,897,574*	*53,656,833,607*
8	Non-controlling interest	429		26,961,187,119	28,529,266,796
	TOTAL RESOURCES (440=300+400)	**440**		**1,712,850,909,268**	**1,931,917,272,419**

Hanoi, October 28, 2026

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Prepared by	Chief Accountant	General Director
Nguyen Hai Trieu	Dinh Nam Ha	Osamu Yomogida

Form B02a- DN/HN

CONSOLIDATED INCOME STATEMENT

For the period from 01/07/2026 to 30/09/2026

Unit: VND

ITEMS	Codes	Notes	Quarter III		Accumulated from the beginning of the year	
			Year 2026	Year 2025	Year 2026	Year 2025
1 Gross revenue from goods sold and services rendered	**01**	**II.1**	**544,334,842,595**	**638,969,901,939**	**1,689,131,187,307**	**1,709,539,464,818**
2 Revenue deductions	02	II.2	283,302,244	169,092,560	332,278,006	378,961,630
3 Net revenue from goods sold and services rendered (10=01-02)	**10**	**II.3**	**544,051,540,351**	**638,800,809,379**	**1,688,798,909,301**	**1,709,160,503,188**
4 Cost of sales	11	II.4	497,080,043,959	589,086,852,357	1,552,941,792,916	1,552,120,897,958
5 Gross profit from goods sold and services rendered (20 =10-11)	**20**		**46,971,496,392**	**49,713,957,022**	**135,857,116,385**	**157,039,605,230**
6 Gain/Loss from the sale, liquidation of investment propert	21		-	-	-	-
7 Financial income	22	II.5	3,534,843,252	5,679,495,204	15,721,789,134	21,952,289,063
8 Financial expenses	23	II.6	5,296,199,530	3,673,716,326	11,823,440,180	16,919,529,390
In which: Interest expense	*24*		*5,064,226,124*	*3,170,986,255*	*10,822,889,317*	*10,298,212,042*
9 Selling expenses	25	II.9	8,391,421,205	7,706,914,709	32,100,762,697	23,423,246,690
10 General and administration expenses	26	II.9	42,842,267,778	35,641,878,907	95,270,045,533	96,417,669,085
11 Profit or loss from associates, joint ventures	27		410,612,372	1,535,829,592	1,406,619,921	6,525,263,077
11 Operating profit {30 = 20 + 21 +(22- 23) - (25 + 26)+27}	**30**		**(5,612,936,497)**	**9,906,771,876**	**13,791,277,030**	**48,756,712,205**
13 Other income	31	II.7	15,868,233,770	4,169,103,548	22,987,904,076	11,622,344,201
14 Other expenses	32	II.8	639,375,456	-	1,414,481,182	630,379,075
15 Profit from other activities (40=31-32)	**40**		**15,228,858,314**	**4,169,103,548**	**21,573,422,894**	**10,991,965,126**

16 Accounting profit before tax (50=30+ 40)	**50**		**9,615,921,817**	**14,075,875,424**	**35,364,699,924**	**59,748,677,331**
17 Current CIT expense	51	II.10	3,433,581,838	2,551,656,407	8,648,826,234	10,904,517,392
18 Deferred CIT expense	52		329,662,804	-	472,055,793	-
19 Net profit after corporate income tax (60=50-51-52)	**60**		**5,852,677,175**	**11,524,219,017**	**26,243,817,897**	**48,844,159,939**
20 The Parent company's net profit after tax	61		6,821,978,209	13,008,856,734	27,811,897,574	47,494,758,363
21 The non-controlling interests shareholders' net profit after tax	62		(969,301,034)	(1,484,637,717)	(1,568,079,677)	1,349,401,576

Hanoi, October 28, 2026

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Prepared by	Chief Accountant	General Director
Nguyen Hai Trieu	Dinh Nam Ha	Osamu Yomogida

Form B03a - DN/HN

INTERIM CONSOLIDATED CASH FLOWS STATEMENT

(Under indirect method)

For the period from 01/07/2026 to 30/09/2026

Unit: VND

ITEMS	Codes	Notes	Quarter III		Accumulated from the beginning of the year	
			Year 2026	Year 2025	Year 2026	Year 2025
I. Cash flow from operating activities						
1. Profit before tax	***01***		***9,615,921,817***	***14,075,875,424***	***35,364,699,924***	***59,748,677,331***
2. *Adjustments for*						
- Depreciation of fixed assets and investment properties	02		16,250,172,956	3,120,889,527	28,610,285,649	15,051,502,741
- Provisions	03		-	-	(68,538,536)	212,849,489
- Foreign exchange gain/loss arising from translating foreign currency items	04		907,596,535	(4,951,541,341)	(79,884,639)	348,185,862
- Gain, loss from investing activities	05		(876,694,114)	(3,527,495,923)	(5,364,424,273)	(16,452,601,503)
- Interest expense	06		5,064,226,124	3,170,986,255	10,822,889,317	10,298,212,042
- Other adjustments	07		-	-	-	-
3. Profit from operating activities before changes in working capital	***08***		***30,961,223,318***	***11,888,713,942***	***69,285,027,442***	***69,206,825,962***
- Increases, decreases in receivables	09		(20,663,070,238)	36,026,080,665	(30,093,255,027)	44,996,582,689
- Increases, decreases in inventories	10		53,037,997,031	(32,729,032,513)	199,558,094,180	(56,413,191,029)
- Increases, decreases in payables (excluding interest payable, corporate income tax payable)	11		(2,401,586,827)	8,700,253,608	(136,213,588,844)	107,194,007,356
- Increases, decreases in prepayment expense	12		(5,783,523,911)	534,863,987	(7,381,832,111)	794,120,404
- Interest expense paid	14		(6,185,892,875)	(4,167,072,120)	(12,009,786,406)	(11,340,310,432)
- Corporate income tax paid	15		(4,511,768,097)	(2,928,429,738)	(11,204,943,968)	(13,422,937,700)
- Other cash outflows	17		(145,300,000)	(10,600,000)	(2,955,938,800)	(189,562,877)
Net cash flow from operating activities	***20***		***44,308,078,401***	***17,314,777,831***	***68,983,776,466***	***140,825,534,373***

II. Cash flow from investing activities						
1. Acquisition and construction of fixed assets and other non-current assets	21		(7,728,757,371)	-	(16,676,415,348)	(37,500,645,964)
2. Proceeds from liquidation, disposal of fixed assets and other non-current assets	22		10,000,000,000	2,957,217,482	10,000,000,000	113,636,364
3. Cash outflows for lending, buying debt instruments of other entities	23		(90,495,890,435)	(350,000,000,000)	(210,000,000,000)	(420,000,000,000)
4. Cash recovered from lending, selling debt instruments of other entities	24		91,967,871,447	260,000,000,000	261,967,871,447	350,000,000,000
5. Cash recovered from capital investment of other entities	26		-	-	-	8,000,000,000
6. Interest earned, dividends and profits received	27		4,632,098,968	3,282,725,627	8,123,821,578	6,544,765,281
Net cash flow from investing activities	*30*		*8,375,322,609*	*(83,760,056,891)*	*53,415,277,677*	*(92,842,244,319)*
III. Cash flow from financial activities						
1. Proceeds from borrowing	33		95,032,989,687	142,819,156,374	303,768,031,563	524,082,210,741
2. Repayment of borrowing	34		(95,116,246,207)	(186,292,047,147)	(393,198,384,695)	(615,136,920,329)
Net cash flow from financial activities	*40*		*(83,256,520)*	*(43,472,890,773)*	*(89,430,353,132)*	*(91,054,709,588)*
Net cash flow in the period (50 = 20+30+40)	**50**		**52,600,144,490**	**(109,918,169,833)**	**32,968,701,011**	**(43,071,419,534)**
Cash and cash equivalents at the beginning of the period	**60**		**64,785,701,868**	**157,117,080,604**	**84,407,566,361**	**90,269,672,873**
Effect of changes in foreign exchange rates	61		(9,578,986)	(657,432)	-	-
Cash and cash equivalents at the end of the period (70= 50+60+61)	**70**	**I.01**	**117,376,267,372**	**47,198,253,339**	**117,376,267,372**	**47,198,253,339**

Hanoi, October 28, 2026

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Prepared by	Chief Accountant	General Director
Nguyen Hai Trieu	Dinh Nam Ha	Osamu Yomogida

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS *(continued)*

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

I. Additional information of items presented in the Consolidated Balance Sheet

1. Cash and cash equivalents

	30/09/2026 VND	01/01/2026 VND
Cash	**61,676,267,372**	**74,036,751,569**
Cash on hand	***15,475,225,083***	***5,265,522,207***
Cash in bank	***46,201,042,289***	***68,771,229,362***
VND	45,707,377,930	68,646,493,402
USD	483,090,044	113,685,066
EUR	10,574,315	11,050,894
Cash equivalents (*)	**55,700,000,000**	**10,370,814,792**
Bank deposits with terms of less than 3 months (*)	55,700,000,000	10,370,814,792
Total	**117,376,267,372**	**84,407,566,361**

(*) Bank deposits with joint-stock commercial banks with terms ranging from 1month to 3 months.

2. Financial investments

a) Held-to-maturity investments

	30/09/2026 VND		01/01/2026 VND	
	Cost	Carrying amount	Cost	Carrying amount
Short-term	**100,286,027,330**	**100,286,027,330**	**153,045,424,635**	**153,045,424,635**
Vietnam Joint Stock Commercial Bank for Industry and Trade - Thanh An Branch (*)	-	-	81,904,219,178	81,904,219,178
Viet A Commercial Joint Stock Bank - Ha Dong Branch (*)	60,286,027,330	60,286,027,330	30,546,356,141	30,546,356,141
Vietnam Technological and Commercial Joint Stock Bank – Dong Do Branch (*)	40,000,000,000	40,000,000,000	40,594,849,316	40,594,849,316
Total	**100,286,027,330**	**100,286,027,330**	**153,045,424,635**	**153,045,424,635**

(*) Term deposit contracts with commercial banks, with interest rates specified in each contract.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS *(continued)*

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

b) Investment in other entities

	30/09/2026 VND			01/01/2026 VND		
	Cost	Adjustment in the period	Book value	Cost	Adjustment in the period	Book value
Investment in associates						
Southern Hataphar Company Limited (i)	700,000,000	302,492,981	1,002,492,981	700,000,000	124,961,667	824,961,667
Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC (ii)	2,450,000,000	17,199,325,834	19,649,325,834	2,450,000,000	16,585,331,290	19,035,331,290
Total	**3,150,000,000**	**17,501,818,815**	**20,651,818,815**	**3,150,000,000**	**16,710,292,957**	**19,860,292,957**

- Summary of the operations of the associated companies during the period:

(i) Under the 7th amended Business Registration Certificate dated June 15, 2017, the Company invested VND 700,000,000 in Southern Hataphar Company Limited, equivalent to 48.28% of the charter capital. At the end of the year, the Company invested VND 700,000,000, equivalent to 48.28% of the charter capital.

(ii) Under the 2nd amended Business Registration Certificate dated June 20, 2023, the Company invested VND 4,900,000,000 in Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC, equivalent to 49% of the charter capital. During the period, the Company received stock dividends in the amount of 490,000 shares. At the end of the accounting period, the Company held 49% of the charter capital, equivalent to 980,000 shares of Hataphar Healthcare Vietnam High-Tech Pharmaceutical Joint Stock Company (the beginning of the year balance was 490,000 shares, equivalent to 49% of the charter capital). According to the 3rd amended Business Registration Certificate dated June 11, 2025, the Company invested in Vietnam Hataphar Healthcare High Technology Pharmaceutical Joint Stock Company with a value of VND 9,800,000,000, equivalent to 49% of the charter capital.

The associated companies are functioning normally, with no significant changes compared to the previous year.

As at September 30, 2026, it has not been possible to determine the fair value of the investments mentioned above due to a lack of market prices or insufficient information needed for assessment. The fair value of these investments may differ from their book value.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS *(continued)*

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

3. Trade receivable

	30/09/2026 VND		01/01/2026 VND	
	Amount	Provision	Amount	Provision
Short-term	**129,888,272,495**	**(3,100,934,958)**	**111,636,095,800**	**(3,169,473,494)**
- Some large balances in trade receivables:				
Vietnam Hataphar Healthcare High Technology	13,076,873,961	-	40,103,925,920	-
Dong Do Pharmaceutical Company Limited	18,136,825,054	-	-	-

4. Advances to suppliers

	30/09/2026 VND		01/01/2026 VND	
	Amount	Provision	Amount	Provision
Short-term	**35,487,273,121**	**(711,672,000)**	**37,840,076,173**	**(711,672,000)**
- Some large balances in Advances to suppliers:				
Bliss Pharma distribution and consul Tancy corp	415,170,000	-	415,170,000	-
Pharmametics products a division of max Biocare Pty	9,408,141,816	-	9,408,141,816	-
Delta Pharma Ltd	1,516,328,883	-	1,516,328,883	-
Inbiotech Ltd	646,177,815	-	646,177,815	-

5. Other receivables

		30/09/2026 VND		01/01/2026 VND	
		Amount	Provision	Amount	Provision
a)	**Short - term**	**411,872,532**	-	**294,439,301**	-
	Other receivables	***33,496,071***	-	***163,462,990***	-
	Others	33,496,071	-	163,462,990	-
	Advances	***378,376,461***	-	***130,976,311***	-
	Nguyen Van Phuc	187,518,871	-	-	-
	Others	190,857,590	-	130,976,311	-
b)	**Long - term**	**6,407,042,500**	-	**6,407,042,500**	-
	Mortgages, deposits	**6,407,042,500**	-	**6,407,042,500**	-
	Management Board of Hoa Lac High-Tech Park (*)	6,407,042,500	-	6,407,042,500	-
	Total	**6,818,915,032**	-	**6,701,481,801**	-

(*) The deposit for the Management Board of Hoa Lac High-Tech Park to ensure the implementation of the "Hataphar High-Tech Pharmaceutical Factory" is outlined in the Investment Project Implementation Guarantee Deposit Agreement No. 06/TTKQ dated November 27, 2020.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS *(continued)*

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

6. Bad debts

	30/09/2026 VND		01/01/2026 VND	
	Cost	Recoverable amount	Cost	Recoverable amount
Total value of receivables, that are overdue and difficult to recover				
Trade receivables	**3,460,368,948**	**359,433,990**	**3,539,882,618**	**370,409,124**
Thu Duc City Hospital	1,774,525,000	102,665,000	1,774,525,000	102,665,000
Others	1,685,843,948	256,768,990	1,765,357,618	267,744,124
Advances to suppliers	**711,672,000**	-	**711,672,000**	-
ERP Solutions Joint Stock Company	711,672,000	-	711,672,000	-
Total	**4,172,040,948**	**359,433,990**	**4,251,554,618**	**370,409,124**

7. Inventories

	30/09/2026 VND		01/01/2026 VND	
	Cost	Provision	Cost	Provision
Purchased goods in transit	63,775,740,695	-	127,357,336,205	-
Raw materials	75,849,315,718	-	74,584,107,934	-
Tools and supplies	279,756,435	-	342,444,153	-
Work in progress	13,038,839,086	-	9,735,832,625	-
Finished goods	55,921,362,315	-	23,437,595,070	-
Goods	104,973,851,118	-	277,939,643,560	-
Total	**313,838,865,367**	-	**513,396,959,547**	-

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS *(continued)*

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

8. Increases, decreases in tangible fixed assets

Unit: VND

Items	Building and structures	Machinery, equipment	Means of transport, transmission equipment	Office equipment and tools	Other fixed assets	Total
Cost						
Balance as at 01/01/2026	**168,479,750,526**	**259,122,286,133**	**13,999,342,253**	**4,451,386,943**	**439,282,500**	**446,492,048,355**
Purchase in the priod	-	2,347,215,926	-	138,687,000	-	**2,485,902,926**
Construction completed	414,760,846,073	317,814,954,679	66,903,781,902	718,695,935	-	**800,198,278,589**
Reclassify	-	(57,806,077,051)	110,075,000	(58,575,000)	-	**(57,754,577,051)**
Liquidation of fixed assets	(3,188,910,590)	(3,782,791,929)	-	(45,714,286)	-	**(7,017,416,805)**
Balance as at 30/09/2026	**580,051,686,009**	**517,695,587,758**	**81,013,199,155**	**5,204,480,592**	**439,282,500**	**1,184,404,236,014**
Accumulated depreciation						
Balance as at 01/01/2026	**101,863,548,983**	**159,551,744,355**	**7,193,456,388**	**3,912,375,063**	**439,282,500**	**272,960,407,289**
Depreciation in the period	8,516,476,121	18,117,418,293	1,850,582,941	125,808,295	-	**28,610,285,649**
Liquidation of fixed assets	(3,188,910,586)	(3,645,291,929)	-	(45,714,286)	-	**(6,879,916,801)**
Balance as at 30/09/2026	**107,191,114,518**	**174,023,870,719**	**9,044,039,329**	**3,992,469,072**	**439,282,500**	**294,690,776,137**
Net book value						
As at 01/01/2026	**66,616,201,543**	**99,570,541,778**	**6,805,885,865**	**539,011,880**	-	**173,531,641,066**
As at 30/09/2026	**472,860,571,491**	**343,671,717,039**	**71,969,159,826**	**1,212,011,520**	-	**889,713,459,877**

- Historical cost of fixed assets which have been fully depreciated but still in use as at 30/09/2026: VND 155.223.458.205 (As at 31/12/2025: VND 164,095,739,856)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS *(continued)*

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

9. Increases, decreases in intangible fixed assets

Unit: VND

Items	Accounting software	Land use rights	Total
Cost			
Balance as at 01/01/2026	**650,000,000**	**1,376,660,000**	**2,026,660,000**
Balance as at 30/09/2026	**650,000,000**	**1,376,660,000**	**2,026,660,000**
Accumulated amortization			
Balance as at 01/01/2026	**650,000,000**	**-**	**650,000,000**
Balance as at 30/09/2026	**650,000,000**	**-**	**650,000,000**
Net book value			
As at 01/01/2026	**-**	**1,376,660,000**	**1,376,660,000**
As at 30/09/2026	**-**	**1,376,660,000**	**1,376,660,000**

- Historical cost of intangible fixed assets which have been fully depreciated but still in use: VND 650,000,000. (As at 31/12/2025: VND 650,000,000)

10. Construction in progress

	30/09/2026 VND	01/01/2026 VND
Hataphar High-Tech Pharmaceutical Factory (*)	1,700,433,384	807,746,227,200
AQP assessment costs	-	1,277,777,778
Cost of research and development of pharmaceutical products	-	14,559,878,894
Purchasing fixed assets	-	925,925,926
Factory renovation	9,353,143,304	2,674,508,863
Total	**11,053,576,688**	**827,184,318,661**

(*) The Hataphar High-Tech Pharmaceutical Manufacturing Factory investment project is implemented according to Decision No. 163/QD-CNCHL dated October 07, 2020. The project covers an area of 45,188 m2 located at Lot CN1-03A-1, CN1-03A-2, CN1-03A-3, High-Tech Industrial Park 1, Hoa Lac High-Tech area, Thach That commune, Hanoi, with a total investment of VND 1,283 billion. The project includes the following main components: Office building and research center; Production factory; and Central warehouse. This project was completed and put into operation in the third quarter of 2026.

11. Prepayments

	30/09/2026 VND	01/01/2026 VND
Long-term		
Issued tools and instruments awaiting for allocation	1,843,510,674	2,465,920,534
Land lease costs for the Hataphar High-Tech Pharmaceutical Plant Project	62,911,794,843	-
Product research and development costs	11,663,916,776	-
Renovation and repair costs	4,459,983,625	2,858,499,091
Other prepaid expenses	6,710,512,062	307,754,625
Total	**87,589,717,980**	**5,632,174,250**

12. Deferred tax assets

	30/09/2026 VND	01/01/2026 VND
Corporate income tax rate used to determine the value of deferred tax assets	**20%**	**20%**
Deferred tax assets relating to deductible temporary differences	713,670,869	1,185,726,662
Total	**713,670,869**	**1,185,726,662**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS *(continued)*

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

13. Trade payables

	30/09/2026 VND		01/01/2026 VND	
	Amount	Amount able to be paid off	Amount	Amount able to be paid off
Short - term	**237,282,018,356**	**237,282,018,356**	**261,260,793,034**	**261,260,793,034**
- Some large balances in Trade payables:				
Dong Au Trading and Production Company Limited	1,608,690,089	1,608,690,089	3,979,856,644	3,979,856,644
Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC	3,136,289,620	3,136,289,620	5,817,834,883	5,817,834,883
KPC Pharmaceuticals, Inc	23,564,450,840	23,564,450,840	19,025,983,320	19,025,983,320
XL Laboratories PVT.,LTD	-	-	22,359,757,441	22,359,757,441
Pharmaunity Co.,Ltd	-	-	13,349,510,483	13,349,510,483
Bliss pharma distribution and	40,993,472,156	40,993,472,156	40,758,864,060	40,758,864,060
Wockhardt Limited	27,379,879,924	27,379,879,924	10,056,600,528	10,056,600,528
Pharmametics products a division of max Biocare	28,523,500,250	28,523,500,250	13,799,528,479	13,799,528,479

14. Advances from customers

	30/09/2026 VND	01/01/2026 VND
Short - term	**60,393,032,031**	**177,983,077,668**
- Some large balances in Advances from customers:		
T&T Pharmaceutical and Trading JSC	2,645,100,135	6,442,145,755
Life Pharmaceutical and Medical Equipment Joint Stock Company	17,463,852,655	7,278,056,310
Dong Do Pharmaceutical Company Limited	18,136,825,054	2,502,291,750
TB Vietnam Pharmaceutical Trading Company Limited	-	49,761,555,583
Phap Pharmaceutical Joint Stock Company	-	28,976,548,644
Thuan An Phat Pharmaceutical Joint Stock Company	-	10,784,000,000

15. Taxes and amounts payable to the State budget

Unit: VND

Items	01/01/2026	Payable during the period	Paid during the period	30/09/2026
Short-term payables				
Output value added tax	841,144,007	11,484,424,934	12,325,568,941	-
Value added tax on imports	-	19,130,141,497	19,130,141,497	-
Import tax	-	978,988,525	978,988,525	-
Corporate income tax	4,550,220,339	8,648,826,234	11,204,943,968	1,994,102,605
Personal income tax	123,688,693	3,208,552,232	2,714,786,312	617,454,613
Housing tax, land rent	-	2,217,735,637	2,217,735,637	-
Resource Tax	-	11,926,600	11,926,600	-
Fees, charges and other payables	-	-	-	-
Total	**5,515,053,039**	**45,680,595,659**	**48,584,091,480**	**2,611,557,218**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS *(continued)*

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

16. Accrued expenses

	30/09/2026	01/01/2026
	VND	VND
Short-term		
Accrued interest expense	98,653,892	161,520,303
Accrued land rental expenses	1,200,000,000	-
Total	**1,298,653,892**	**161,520,303**

17. Unearned revenue

	30/09/2026	01/01/2026
	VND	VND
Short-term		
Unearned revenue from leases	1,228,062,420	575,370,229
Unrealized revenue corresponding to inventory not yet sold to external parties by the associate in intercompany transactions	3,409,841,426	5,842,716,077
Total	**4,637,903,846**	**6,418,086,306**

18. Other payables

		30/09/2026	01/01/2026
		VND	VND
a)	**Short-term**	**1,529,940,250**	**783,924,677**
	Insurance	396,139,585	592,397,733
	Other payables	1,133,800,665	191,526,944
b)	**Long-term**	**3,438,300,000**	**3,625,600,000**
	Long-term collaterals, deposits received	3,438,300,000	3,625,600,000
	Total	**4,968,240,250**	**4,409,524,677**

19. Loans and obligations under finance lease

Loans

Unit: VND

	30/09/2026		In the period		01/01/2026	
	Amount	Amount able to be paid off	Increases	Decreases	Amount	Amount able to be paid off
a) Short-term	**160,565,050,276**	**160,565,050,276**	**303,768,031,563**	**393,198,384,695**	**249,995,403,408**	**249,995,403,408**
Short-term loans	***146,720,342,351***	***146,720,342,351***	***303,768,031,563***	***393,198,384,695***	***236,150,695,483***	***236,150,695,483***
Vietnam Joint Stock Commercial Bank for Industry and Trade - Thanh An Branch (1)	38,975,771,829	38,975,771,829	55,630,209,760	47,150,253,780	30,495,815,849	30,495,815,849
Joint Stock Commercial Bank for Foreign Trade of Vietnam - Ha Tay Branch (2)	32,314,716,315	32,314,716,315	66,240,337,086	96,238,232,730	62,312,611,959	62,312,611,959
Shinhan Bank Vietnam Limited - Hanoi Branch (3)	28,620,229,843	28,620,229,843	84,961,274,419	108,391,905,565	52,050,860,989	52,050,860,989
Joint Stock Commercial Bank for Investment and Development of Vietnam - Ngoc Khanh Branch (4)	24,938,913,308	24,938,913,308	63,998,678,985	63,469,669,922	24,409,904,245	24,409,904,245
Vietnam Bank for Agriculture and Rural Development – Hanoi II Branch (5)	-	-	21,118,721,175	41,952,072,044	20,833,350,869	20,833,350,869
Personal loans (6)	21,870,711,056	21,870,711,056	11,818,810,138	35,996,250,654	46,048,151,572	46,048,151,572
Long-term loans on due date	***13,844,707,925***	***13,844,707,925***	-	-	***13,844,707,925***	***13,844,707,925***
MUFG Bank, LTD - Hanoi Branch (7)	13,844,707,925	13,844,707,925	-	-	13,844,707,925	13,844,707,925
b) Long-term loans	**83,068,247,547**	**83,068,247,547**	-	-	**83,068,247,547**	**83,068,247,547**
MUFG Bank, LTD - Hanoi Branch (7)	83,068,247,547	83,068,247,547	-	-	83,068,247,547	83,068,247,547
Total	**243,633,297,823**	**243,633,297,823**	**303,768,031,563**	**393,198,384,695**	**333,063,650,955**	**333,063,650,955**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS *(continued)*

Form B 09a - DN/HN

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

(1) Credit Contract No. 3110/2025-HDCVHM/NHCT320-HATAPHAR dated October 31, 2025, loan limit of VND 300 billion (including debts adjusted by Credit Contract No. 2209/2024-HDCVHM/NHCT320-HATAPHAR dated September 22, 2024), loan purpose: supplementing working capital for production and business activities; loan interest rate is the interest rate stated on each indebtedness certificate and is valid from the time of disbursement until the interest rate is adjusted; the loan term of each debt is stated on the indebtedness certificate but not exceeding 5 months/indebtedness certificate from the time of loan disbursement; Limit maintenance period until October 31, 2026; unsecured loan.

(2) Loan contract under the limit No. 15/26/QLN/HM/VCBTHN dated March 20, 2026 attached to the credit contract No. 15/26/QLN/CTD/VCBTHN dated March 20, 2026, the contract for issuing letters of credit under the limit No. 15/26/QLN/HMLC/VCBTHN dated March 20, 2026, the credit guarantee agreement under the limit No. 15/26/QLN/HMBL/VCBTHN dated March 20, 2026, the loan limit is VND 200 billion (including the limit of the loan contract under the limit No. 04/25/QLN/HM/VCBTHN dated February 02, 2025), the purpose of the loan is to finance short-term borrowing needs. legal, reasonable, valid to serve the production and business activities of the Customer but does not include short-term needs to serve fixed asset investment activities, interest rates are specifically regulated for each debt receipt; the loan term of each debt is a maximum of 05 months; the credit term is 12 months from the date of signing the contract or until April 12, 2027, whichever comes first; the loan is unsecured.

(3) Credit contract No. 130002065517 dated August 16, 2019 and extension - amendment supplement No. 130002065517/11 dated August 16, 2025 extending the limit until August 15, 2026, the loan limit is VND 80 billion, the purpose of the loan is to supplement working capital for production and business activities; loan interest rate: in case of fixed interest rate for the loan, the fixed interest rate is applied throughout the loan term according to the interest rate specified on the Drawdown Applications and Acknowledgement of Debt of each loan, in case of adjusted interest rate: apply the 3-month MFC reference interest rate plus (+) Margin of 0.74%/year and adjust every 3 months throughout the loan term; The term of each credit is within the limit specified in each indebtedness certificate but does not exceed 05 months/Acknowledgement of Debt; the loan is unsecured.

(4) Credit limit contract No. 01/2026/177578/HDTD dated June 18, 2026; regular credit limit with a maximum amount of VND 200 billion; loan purpose: supplementing working capital, guarantee, opening L/C; interest rate is determined in each specific contract according to the Bank's interest rate regime in each period; credit limit period is 12 months from the date of signing this Contract but not exceeding June 30, 2027; the loan is unsecured.

(5) Credit contract No. 1505-LAV-202500773 dated July 02, 2025 and Appendix No. 01 dated July 03, 2025, the loan limit is VND 30 billion, loan purpose and L/C payment: supplement working capital to support the company's production and business activities in 2025-2026; the loan interest rate will be a variable rate as stipulated by the bank at the time of loan disbursement; he loan term will be as specified in each debt acknowledgement but not exceeding 6 months; the credit limit will be granted for 12 months from the date of signing this

(6) Individuals loans according to each loan contract, for the purpose of serving the Company's production and business activities; loan term of less than 12 months; interest rate from 2%/year to 6.5%/year.

(7) Long-term Facility letter No. FL/053/22 dated August 02, 2022, Amendment agreement No. 02 dated January 17, 2023, Amendment agreement No. 03 dated December 27, 2023 of Long-term Facility Letter No. FL/053/22 dated August 02, 2022, the aggregate principal sum of the Facility shall not exceed VND 235 billion. The loan term until December 31, 2032, the Facility shall be used for Capital Expenditure/Factory Construction and for no other purpose. The specific interest rate for the first interest period in respect of an advance specified in a request for Advance which forms an inseparable part of such request shall be legally bound from the moment of the Customer and the Bank agree to such interest rate (whether orally or otherwise) and the request for Advance is deemed to have been accepted by the Bank from that moment thereof. The specific interest rate and other terms of the Advance shall be thereafter documented for evidentiary purposes in a notice (the "Advance") delivered by the Bank to the Customer. This loan is secured by the letter of guarantee issued by Aska Pharmaceutical Holdings Co., Ltd dated August 02, 2022. The first installment of each Advance shall be on the last Business day of December 2025, the subsequent installment shall be made every 12 months thereafter.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

Form B 09a - DN/HN

20. Owner's equity

20.1 Movement in owner's equity

Unit: VND

Items	Owner's contributed capital	Share premium	Other owners' equity	Treasury shares (*)	Investment and development fund	Retained earnings	Non-controlling interest	Total
Balance as at 01/01/2025	**823,417,730,000**	**97,320,000,000**	**26,612,306,630**	**(8,083,874,357)**	**10,749,248,213**	**79,530,817,489**	**27,214,093,742**	**1,056,760,321,717**
Increase in owner's contributed capital from share premium	60,037,780,000	(60,037,780,000)	-	-	-	-	-	-
Increase in owner's contributed capital from retained earnings	22,300,000,000	-	-	-	-	(22,300,000,000)	-	-
Profit in previous year	-	-	-	-	-	53,656,833,607	5,383,623,054	59,040,456,661
Dividend payment	-	-	-	-	-	-	(4,068,450,000)	(4,068,450,000)
Other decreases	-	-	-	-	-	(531,684,054)	-	(531,684,054)
Balance as at 31/12/2025	**905,755,510,000**	**37,282,220,000**	**26,612,306,630**	**(8,083,874,357)**	**10,749,248,213**	**110,355,967,042**	**28,529,266,796**	**1,111,200,644,324**
Transfer of other owners' capital to retained earnings (**)	-	-	(24,375,893,101)	-	-	24,375,893,101	-	-
Profit in this period	-	-	-	-	-	27,811,897,574	(1,568,079,677)	26,243,817,897
Other decreases	-	-	-	-	-	(615,094,063)	-	(615,094,063)
Balance as at 30/09/2026	**905,755,510,000**	**37,282,220,000**	**2,236,413,529**	**(8,083,874,357)**	**10,749,248,213**	**161,928,663,654**	**26,961,187,119**	**1,136,829,368,158**

(*) The book value of shares purchased by the subsidiary from the parent company prior to July 01, 2015.

(**) Transfer of other owners' capital to retained earnings, as proposed in Submission No. 152/TTr-DHT dated February 10, 2026, and approved under Resolution No. 219/NQ-DHT dated March 30, 2026, of the 2026 Annual General Meeting of Shareholders of Ha Tay Pharmaceutical Joint Stock Company.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS *(continued)*

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

20.2 Details of owner's equity contribution

	30/09/2026 VND	01/01/2026 VND
Hanoi Investment Fund for Development	34,076,520,000	34,076,520,000
ASKA Pharmaceutical Co., Ltd	362,727,620,000	362,727,620,000
Le Van Lo	50,819,900,000	50,819,900,000
Ngo Van Chinh	22,195,920,000	22,195,920,000
Hoang Van Tue	36,153,210,000	36,153,210,000
Le Viet Linh	57,441,840,000	57,441,840,000
Le Anh Trung	33,718,720,000	33,718,720,000
Le Xuan Thang	35,205,290,000	35,205,290,000
Ngo Tuan Viet	5,500,000,000	5,500,000,000
Others	267,916,490,000	267,916,490,000
Total	**905,755,510,000**	**905,755,510,000**

20.3 Capital transactions with owners, dividend distribution and shared profit

	Quarter III/2026 VND	Quarter III/2025 VND
Owners' contributed capital		
Contributed at current period's opening balance	905,755,510,000	823,417,730,000
Contributed capital increase during the period	-	-
Contributed at current period's closing balance	905,755,510,000	823,417,730,000
Paid dividend, shared profit	-	-

20.4 Shares

	30/09/2026 Shares	01/01/2026 Shares
Number of shares registered for issue	90,575,551	90,575,551
Number of shares issued to the public	90,575,551	90,575,551
- Ordinary shares	*90,575,551*	*90,575,551*
- Preferred shares	-	-
Number of shares bought back	1,513	1,513
- Ordinary shares	*1,513*	*1,513*
- Preferred shares	-	-
Number of outstanding shares in circulation	90,574,038	90,574,038
- Ordinary shares	*90,574,038*	*90,574,038*
- Preferred shares	-	-

Par value of outstanding shares: VND 10,000/share

20.5 Dividends

Dividends declared after the end of the accounting period:
- Dividends declared on ordinary shares: no
- Dividends declared on preferred shares: no

Unrecorded cumulative preferred shares dividends: no

20.6 Funds of the Company

Unit: VND

Items	01/01/2026	Increase	Decrease	30/09/2026
Investment and development fund	10,749,248,213	-	-	10,749,248,213
Total	**10,749,248,213**	-	-	**10,749,248,213**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS *(continued)*

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

II. Additional information for items presented in the Consolidated Income Statement

1. Gross revenue from goods sold and services rendered

	Quarter III/2026 VND	Quarter III/2025 VND
Revenue from sales of finished products	117,040,447,636	162,996,809,684
Revenue from sales of goods	427,294,394,959	475,973,092,255
Total	**544,334,842,595**	**638,969,901,939**

2. Revenue deductions

	Quarter III/2026 VND	Quarter III/2025 VND
Sales returns	283,302,244	169,092,560
Total	**283,302,244**	**169,092,560**

3. Net revenue from goods sold and services rendered

	Quarter III/2026 VND	Quarter III/2025 VND
Net revenue from sales of finished products	116,757,145,392	162,827,717,124
Net revenue from sales of goods	427,294,394,959	475,973,092,255
Total	**544,051,540,351**	**638,800,809,379**

4. Cost of sales

	Quarter III/2026 VND	Quarter III/2025 VND
Cost of finished products sales	81,384,741,940	120,900,001,296
Cost of goods sales	415,695,302,019	468,186,851,061
Total	**497,080,043,959**	**589,086,852,357**

5. Financial income

	Quarter III/2026 VND	Quarter III/2025 VND
Financial income	3,534,843,252	5,679,495,204
Total	**3,534,843,252**	**5,679,495,204**

6. Financial expenses

	Quarter III/2026 VND	Quarter III/2025 VND
Interest expense	5,064,226,124	3,170,986,255
Exchange rate difference losses and others financial expenses	231,973,406	502,730,071
Total	**5,296,199,530**	**3,673,716,326**

7. Other income

	Quarter III/2026 VND	Quarter III/2025 VND
Other income	15,868,233,770	4,169,103,548
Total	**15,868,233,770**	**4,169,103,548**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS *(continued)*

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

8. Other expenses

	Quarter III/2026 VND	Quarter III/2025 VND
Other expenses	639,375,456	-
Total	**639,375,456**	**-**

9. Selling expenses and general and administration expenses

		Quarter III/2026 VND	Quarter III/2025 VND
a)	Selling expenses incurred in the period	8,391,421,205	7,706,914,709
b)	General administration expenses incurred in the period	42,842,267,778	35,641,878,907
	Total	**51,233,688,983**	**43,348,793,616**

10. Current corporate income tax expense

	Quarter III/2026 VND	Quarter III/2025 VND
Corporate income tax expense calculated on current taxable income	3,433,581,838	2,551,656,407
Adjustment of Corporate income tax expense in prior years into current Corporate income tax this year	-	-
Total current corporate income tax expense	3,433,581,838	2,551,656,407

11. Deferred corporate income tax expense

	Quarter III/2026 VND	Quarter III/2025 VND
Deferred corporate income tax expense arising from deductible temporary differences	329,662,804	-
Total	**329,662,804**	**-**

Hanoi, October 28, 2026

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Prepared by	Chief Accountant	General Director
Nguyen Hai Trieu	Dinh Nam Ha	Osamu Yomogida